November 24, 2020

Notice of Acquisition of Exclusive Sales Rights in Japan and Overseas Priority Sales and Negotiating Rights for Venari Medical's Vascular Treatment Device

Nipro Corporation (Headquarters: Kita-ku, Osaka, President & Representative Director: Yoshihiko Sano) hereby announces that it has acquired exclusive sales rights in Japan and overseas priority sales and negotiating rights for a vascular treatment device developed by Venari Medical Ltd. (Headquarters: Ireland, CEO and co-founder: Stephen Cox) (hereinafter "Venari Medical").

Venari Medical is an Irish venture company engaged in the development of treatment devices for chronic venous disease (CVD). The company is currently working on the development of a vascular treatment device especially for the minimally invasive closure of veins in patients with venous foot ulcers. Through the acquisition of the shares of Venari Medical, we have obtained exclusive sales rights in Japan and overseas priority sales and negotiating rights for this device.

We will make preparations with Venari Medical to launch domestic sales of the product in the first half of 2023.

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Nipro Corporation published this content on 24 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 December 2020 06:44:06 UTC